Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.

Lake JA, Donson AM, Prince E, Davies KD, Nellan A, Green AL, Mulcahy Levy J, Dorris K, Vibhakar R, Hankinson TC, Foreman NK, Ewalt MD, Kleinschmidt-DeMasters BK, Hoffman LM, Gilani A.

Pediatr Blood Cancer. 2019 Oct 8:e28028. doi: 10.1002/pbc.28028. [Epub ahead of print]

PMID:
31595628
2.

Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells.

Zahedi S, Fitzwalter BE, Morin A, Grob S, Desmarais M, Nellan A, Green AL, Vibhakar R, Hankinson TC, Foreman NK, Mulcahy Levy JM.

Cell Death Dis. 2019 Sep 12;10(9):679. doi: 10.1038/s41419-019-1880-y.

3.

Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma.

Grob S, Mirsky DM, Donson AM, Dahl N, Foreman NK, Hoffman LM, Hankinson TC, Mulcahy Levy JM.

Front Oncol. 2019 Aug 21;9:791. doi: 10.3389/fonc.2019.00791. eCollection 2019.

4.

Bevacizumab in the treatment of radiation injury for children with central nervous system tumors.

Dahl NA, Liu AK, Foreman NK, Widener M, Fenton LZ, Macy ME.

Childs Nerv Syst. 2019 Jul 31. doi: 10.1007/s00381-019-04304-y. [Epub ahead of print]

PMID:
31367784
5.

Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.

Pierce AM, Witt DA, Donson AM, Gilani A, Sanford B, Sill M, Van Court B, Oweida A, Prince EW, Steiner J, Danis E, Dorris K, Hankinson T, Handler MH, Jones KL, Karam SD, Serkova NJ, Vibhakar R, Foreman NK, Griesinger AM.

Neuro Oncol. 2019 Jul 4. pii: noz116. doi: 10.1093/neuonc/noz116. [Epub ahead of print]

PMID:
31276586
6.

Global Reduction of H3K4me3 Improves Chemotherapeutic Efficacy for Pediatric Ependymomas.

Lewis R, Li YD, Hoffman L, Hashizume R, Gravohac G, Rice G, Wadhwani NR, Jie C, Pundy T, Mania-Farnell B, Mayanil CS, Soares MB, Lei T, James CD, Foreman NK, Tomita T, Xi G.

Neoplasia. 2019 Jun;21(6):505-515. doi: 10.1016/j.neo.2019.03.012. Epub 2019 Apr 18.

7.

Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.

Merchant TE, Bendel AE, Sabin ND, Burger PC, Shaw DW, Chang E, Wu S, Zhou T, Eisenstat DD, Foreman NK, Fuller CE, Anderson ET, Hukin J, Lau CC, Pollack IF, Laningham FH, Lustig RH, Armstrong FD, Handler MH, Williams-Hughes C, Kessel S, Kocak M, Ellison DW, Ramaswamy V.

J Clin Oncol. 2019 Apr 20;37(12):974-983. doi: 10.1200/JCO.18.01765. Epub 2019 Feb 27.

PMID:
30811284
8.

Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors.

Koo J, Silverman S, Nuechterlein B, Keating AK, Verneris MR, Foreman NK, Mulcahy Levy JM.

Bone Marrow Transplant. 2019 Oct;54(10):1605-1613. doi: 10.1038/s41409-019-0479-3. Epub 2019 Feb 19.

PMID:
30783209
9.

Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma.

Veo B, Danis E, Pierce A, Sola I, Wang D, Foreman NK, Jin J, Ma A, Serkova N, Venkataraman S, Vibhakar R.

JCI Insight. 2019 Jan 10;4(1). pii: 122933. doi: 10.1172/jci.insight.122933. [Epub ahead of print]

10.

Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.

Alimova I, Pierce A, Danis E, Donson A, Birks DK, Griesinger A, Foreman NK, Santi M, Soucek L, Venkataraman S, Vibhakar R.

Int J Cancer. 2019 Apr 15;144(8):1983-1995. doi: 10.1002/ijc.31873. Epub 2019 Jan 10.

PMID:
30230537
11.

Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.

Donson AM, Amani V, Warner EA, Griesinger AM, Witt DA, Levy JMM, Hoffman LM, Hankinson TC, Handler MH, Vibhakar R, Dorris K, Foreman NK.

Mol Cancer Ther. 2018 Sep;17(9):1984-1994. doi: 10.1158/1535-7163.MCT-17-1185. Epub 2018 Jun 20.

12.

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.

Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih CS, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren AO, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M.

J Clin Oncol. 2018 Jul 1;36(19):1963-1972. doi: 10.1200/JCO.2017.75.9308. Epub 2018 May 10.

13.

Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.

Nellan A, Rota C, Majzner R, Lester-McCully CM, Griesinger AM, Mulcahy Levy JM, Foreman NK, Warren KE, Lee DW.

J Immunother Cancer. 2018 Apr 30;6(1):30. doi: 10.1186/s40425-018-0340-z.

14.

Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.

Coy S, Rashid R, Lin JR, Du Z, Donson AM, Hankinson TC, Foreman NK, Manley PE, Kieran MW, Reardon DA, Sorger PK, Santagata S.

Neuro Oncol. 2018 Jul 5;20(8):1101-1112. doi: 10.1093/neuonc/noy035.

15.

Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.

Witt DA, Donson AM, Amani V, Moreira DC, Sanford B, Hoffman LM, Handler MH, Levy JMM, Jones KL, Nellan A, Foreman NK, Griesinger AM.

Pediatr Blood Cancer. 2018 May;65(5):e26960. doi: 10.1002/pbc.26960. Epub 2018 Jan 19.

16.

Intracranial Ewing sarcoma: four pediatric examples.

Yang MJ, Whelan R, Madden J, Mulcahy Levy JM, Kleinschmidt-DeMasters BK, Hankinson TC, Foreman NK, Handler MH.

Childs Nerv Syst. 2018 Mar;34(3):441-448. doi: 10.1007/s00381-017-3684-7. Epub 2017 Dec 28.

17.

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.

Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R.

Oncotarget. 2017 Oct 19;8(57):97290-97303. doi: 10.18632/oncotarget.21932. eCollection 2017 Nov 14.

18.

Survival benefit of postoperative radiation in papillary meningioma: Analysis of the National Cancer Data Base.

Sumner WA, Amini A, Hankinson TC, Foreman NK, Gaspar LE, Kavanagh BD, Karam SD, Rusthoven CG, Liu AK.

Rep Pract Oncol Radiother. 2017 Nov-Dec;22(6):495-501. doi: 10.1016/j.rpor.2017.10.001. Epub 2017 Oct 28.

19.

Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.

Amani V, Donson AM, Lummus SC, Prince EW, Griesinger AM, Witt DA, Hankinson TC, Handler MH, Dorris K, Vibhakar R, Foreman NK, Hoffman LM.

J Neuropathol Exp Neurol. 2017 Jul 1;76(7):595-604. doi: 10.1093/jnen/nlx040.

20.

Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.

Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, Niazi TN, Grant G, Souweidane M, Johnston JM, Jackson EM, Kleinschmidt-DeMasters BK, Handler MH, Tan AC, Gore L, Virasami A, Gonzalez-Meljem JM, Jacques TS, Martinez-Barbera JP, Foreman NK, Hankinson TC; Advancing Treatment for Pediatric Craniopharyngioma Consortium.

J Neuropathol Exp Neurol. 2017 Sep 1;76(9):779-788. doi: 10.1093/jnen/nlx061.

21.

Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study.

Cooney T, Lane A, Bartels U, Bouffet E, Goldman S, Leary SES, Foreman NK, Packer RJ, Broniscer A, Minturn JE, Shih CS, Chintagumpala M, Hassall T, Gottardo NG, Dholaria H, Hoffman L, Chaney B, Baugh J, Doughman R, Leach JL, Jones BV, Fouladi M, Warren KE, Monje M.

Neuro Oncol. 2017 Sep 1;19(9):1279-1280. doi: 10.1093/neuonc/nox107. No abstract available.

22.

p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.

Lummus SC, Donson AM, Gowan K, Jones KL, Vibhakar R, Foreman NK, Kleinschmidt-DeMasters BK.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26656. Epub 2017 May 26.

23.

A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.

Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26621. Epub 2017 May 24.

24.

NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma.

Griesinger AM, Witt DA, Grob ST, Georgio Westover SR, Donson AM, Sanford B, Mulcahy Levy JM, Wong R, Moreira DC, DeSisto JA, Balakrishnan I, Hoffman LM, Handler MH, Jones KL, Vibhakar R, Venkataraman S, Foreman NK.

Neuro Oncol. 2017 Oct 1;19(10):1350-1360. doi: 10.1093/neuonc/nox061.

25.

Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach.

Fay-McClymont TB, Ploetz DM, Mabbott D, Walsh K, Smith A, Chi SN, Wells E, Madden J, Margol A, Finlay J, Kieran MW, Strother D, Dhall G, Packer RJ, Foreman NK, Bouffet E, Lafay-Cousin L.

J Neurooncol. 2017 May;133(1):119-128. doi: 10.1007/s11060-017-2409-9. Epub 2017 Apr 12.

PMID:
28405869
26.

H3 K27M Mutation in Gangliogliomas can be Associated with Poor Prognosis.

Kleinschmidt-DeMasters BK, Donson A, Foreman NK, Dorris K.

Brain Pathol. 2017 Nov;27(6):846-850. doi: 10.1111/bpa.12455. Epub 2017 Apr 5. No abstract available.

PMID:
28378357
27.

Hypofractionated re-irradiation to the brainstem in children with recurrent brain tumors.

Waxweiler TV, Amini A, Vinogradskiy Y, Yeh N, Foreman NK, Hankinson TC, Liu AK.

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26341. Epub 2016 Nov 5.

PMID:
28342300
28.

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.

Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, Kleinschmidt-DeMasters BK, Fitzwalter BE, Goodall ML, Thorburn J, Amani V, Donson AM, Birks DK, Mirsky DM, Hankinson TC, Handler MH, Green AL, Vibhakar R, Foreman NK, Thorburn A.

Elife. 2017 Jan 17;6. pii: e19671. doi: 10.7554/eLife.19671.

29.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DMA, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A.

Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

30.

Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation.

Greer A, Foreman NK, Donson A, Davies KD, Kleinschmidt-DeMasters BK.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26350. Epub 2016 Nov 10.

31.

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD.

Acta Neuropathol. 2017 Jan;133(1):5-12. doi: 10.1007/s00401-016-1643-0. Epub 2016 Nov 17.

32.

Vincristine and Vinblastine: Is checking bilirubin mandatory in children with Brain Tumors?

Madden JR, Evans A, Hemenway M, Stark E, Kissell E, Polito A, Batson D, Stark M, Dhall G, Garvin JH, Foreman NK, Vibhakar R.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26329. Epub 2016 Nov 3. No abstract available.

PMID:
27808466
33.

MPS1 kinase as a potential therapeutic target in medulloblastoma.

Alimova I, Ng J, Harris P, Birks D, Donson A, Taylor MD, Foreman NK, Venkataraman S, Vibhakar R.

Oncol Rep. 2016 Nov;36(5):2633-2640. doi: 10.3892/or.2016.5085. Epub 2016 Sep 12.

34.

Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.

Amani V, Prince EW, Alimova I, Balakrishnan I, Birks D, Donson AM, Harris P, Levy JM, Handler M, Foreman NK, Venkataraman S, Vibhakar R.

BMC Cancer. 2016 Aug 18;16:647. doi: 10.1186/s12885-016-2690-6.

35.

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.

Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R.

Oncotarget. 2016 Aug 16;7(33):53881-53894. doi: 10.18632/oncotarget.10692.

36.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.

Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P.

ACS Chem Biol. 2016 Jul 15;11(7):2066-7. doi: 10.1021/acschembio.6b00466. Epub 2016 Jun 15. No abstract available.

PMID:
27304454
37.

Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy.

Lafay-Cousin L, Smith A, Chi SN, Wells E, Madden J, Margol A, Ramaswamy V, Finlay J, Taylor MD, Dhall G, Strother D, Kieran MW, Foreman NK, Packer RJ, Bouffet E.

Pediatr Blood Cancer. 2016 Sep;63(9):1527-34. doi: 10.1002/pbc.26042. Epub 2016 May 4. Erratum in: Pediatr Blood Cancer. 2017 Apr;64(4):.

38.

SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups.

Kleinschmidt-DeMasters BK, Donson AM, Richmond AM, Pekmezci M, Tihan T, Foreman NK.

J Neuropathol Exp Neurol. 2016 Apr;75(4):295-8. doi: 10.1093/jnen/nlw010. Epub 2016 Mar 4.

39.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.

Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P.

ACS Chem Biol. 2016 Apr 15;11(4):921-30. doi: 10.1021/acschembio.5b00725. Epub 2016 Jan 8. Erratum in: ACS Chem Biol. 2016 Jul 15;11(7):2066-7.

PMID:
26745241
40.

Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK.

Cancer Immunol Res. 2015 Oct;3(10):1165-74. doi: 10.1158/2326-6066.CIR-15-0061. Epub 2015 May 12.

41.

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.

Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR.

J Immunother Cancer. 2014 Dec 16;2(1):46. doi: 10.1186/s40425-014-0046-9. eCollection 2014.

42.

BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK.

Am J Surg Pathol. 2015 Apr;39(4):528-40. doi: 10.1097/PAS.0000000000000363.

43.

Pilomyxoid Astrocytoma (PMA) Shows Significant Differences in Gene Expression vs. Pilocytic Astrocytoma (PA) and Variable Tendency Toward Maturation to PA.

Kleinschmidt-DeMasters BK, Donson AM, Vogel H, Foreman NK.

Brain Pathol. 2015 Jul;25(4):429-40. doi: 10.1111/bpa.12239. Epub 2015 Jan 27.

44.

Using BRAF(V600E) as a marker of autophagy dependence in pediatric brain tumors.

Mulcahy Levy JM, Foreman NK, Thorburn A.

Autophagy. 2014;10(11):2077-8. doi: 10.4161/auto.36138.

45.

Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases.

Lummus SC, Aisner DL, Sams SB, Foreman NK, Lillehei KO, Kleinschmidt-DeMasters BK.

Am J Clin Pathol. 2014 Aug;142(2):254-60. doi: 10.1309/AJCPIBSV67UVJRQV.

46.

Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.

Levy JM, Thompson JC, Griesinger AM, Amani V, Donson AM, Birks DK, Morgan MJ, Mirsky DM, Handler MH, Foreman NK, Thorburn A.

Cancer Discov. 2014 Jul;4(7):773-80. doi: 10.1158/2159-8290.CD-14-0049. Epub 2014 May 13.

47.

Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.

Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, Amani V, Cristiano B, Remke M, Taylor MD, Handler M, Foreman NK, Vibhakar R.

Oncotarget. 2014 May 15;5(9):2355-71.

48.

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.

Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, Zuccaro J, Agnihotri S, Ryall S, Barszczyk M, Chornenkyy Y, Bourgey M, Bourque G, Montpetit A, Cordero F, Castelo-Branco P, Mangerel J, Tabori U, Ho KC, Huang A, Taylor KR, Mackay A, Bendel AE, Nazarian J, Fangusaro JR, Karajannis MA, Zagzag D, Foreman NK, Donson A, Hegert JV, Smith A, Chan J, Lafay-Cousin L, Dunn S, Hukin J, Dunham C, Scheinemann K, Michaud J, Zelcer S, Ramsay D, Cain J, Brennan C, Souweidane MM, Jones C, Allis CD, Brudno M, Becher O, Hawkins C.

Nat Genet. 2014 May;46(5):451-6. doi: 10.1038/ng.2936. Epub 2014 Apr 6.

49.

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R.

Mol Cancer. 2014 Mar 24;13:72. doi: 10.1186/1476-4598-13-72.

50.

Patterns of care for craniopharyngioma: survey of members of the american association of neurological surgeons.

Hankinson TC, Palmeri NO, Williams SA, Torok MR, Serrano CA, Foreman NK, Handler MH, Liu AK.

Pediatr Neurosurg. 2013;49(3):131-6. doi: 10.1159/000357783. Epub 2014 Feb 21.

Supplemental Content

Loading ...
Support Center